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Abstract
Barely 1 year after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first reported in China, the virus 
has infected approximately 120 million people, caused around 3 million deaths, and adversely affected the global economy. 
Despite stringent measures to flatten the epidemiologic curve of the pandemic, there have been spikes and waves of the 
infection in many countries, particularly in the American, European, and Asian continents. This review critically evaluated 
the global epidemiology of the novel coronavirus disease 2019 (COVID-19) to provide advice on other possible ways 
of managing the disease as various COVID-19 vaccines are being rolled out. To effectively control this and possible 
future epidemics/pandemics, there is a need to maintain a healthy balance between saving lives and livelihoods in the 
implementation of lockdowns. Unwarranted human exposures to animals, particularly pangolins, civet cats, bats, dromedary 
camels, and other wildlife known to be reservoirs and intermediate hosts of coronaviruses should be prevented. All the 
identified strains of SARS-CoV-2, including the highly infectious UK and South African variants, should be incorporated 
in COVID-19 vaccine production; to widen the protection spectrum. Some of the COVID-19 vaccines require primary 
inoculation, booster vaccination after 2-4 weeks and annual revaccination for adequate immunization against SARS-CoV-2. 
Survivors of COVID-19 may require only a single vaccine dozing and annual revaccination thereafter. Adoption of One 
Health approach and the development of globally coordinated active surveillance systems against emerging and reemerging 
zoonotic viruses are imperative.
Keywords: COVID-19, coronaviruses, emerging zoonoses, new variant SARS-CoV-2, pandemic diseases, SARS-CoV-2, 
public health.
Introduction
The 2019 novel coronavirus (2019-nCoV) is the 
etiologic agent responsible for clusters of a strange 
form of acute respiratory distress syndrome that 
emanated from China in 2019. The disease was later 
named coronavirus disease 2019 (COVID-19) by the 
World Health Organization (WHO) on February 11, 
2020 [1]. The virus was first isolated from the broncho-
alveolar lavage fluid of suspected COVID-19 patients 
on December 30, 2019, in China [1,2]. After sequenc-
ing and conducting an evolutionary tree analysis of 
the 2019-nCoV, severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2) was the nomenclature 
given to the virus by the WHO and the International 
Committee on Taxonomy of Viruses [1].
SARS-CoV-2 is an enveloped virus with a 
positive-sense single-stranded RNA genome and a 
nucleocapsid of helical symmetry [3]. SARS-CoV-2 
belongs to the genus Betacoronavirus, subfamily 
Orthocoronavirinae, family Coronaviridae, and order 
Nidovirales [4,5]. SARS-CoV and the Middle East 
respiratory syndrome coronavirus (MERS-CoV) are 
also members of the genus Betacoronavirus, which is 
further classified into five subgenera: Embecovirus, 
Hibecovirus, Merbecovirus, Nobecovirus, and 
Sarbecovirus [4-6]. The three human coronaviruses 
(SARS-CoV, MERS-CoV, and SARS-CoV-2) belong 
to the subgenera Sarbecovirus [5]. Genome phylogenic 
analysis indicates that SARS-CoV and MERS-CoV 
have 79% and 50% genomic resemblance with SARS-
CoV-2, respectively [7]. Similarly, the COVID-19 virus 
has approximately 92% genetic resemblance to the 
pangolin coronavirus [8], and this has lent credence to 
the suspicion that SARS-CoV-2 is of animal origin. In 
addition, bats, civet cats and pangolins may play crucial 
roles in the epidemiology of SARS-CoV-2 as the reser-
voirs or intermediate hosts [9,10], as shown in Figure-1.
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SARS-CoV-2 is thought to have emerged from 
an international seafood market in Wuhan city, Hubei 
Province, China, in December 2019 [11]. The China 
global seafood/wildlife market is famous for its 
extensive trade in different species of animals such 
as bats, pangolins, minks, snakes, reptiles, rodents, 
porcupines, and Chinese bamboo rats. Just like other 
zoonotic coronaviruses, there is evidence that SARS-
CoV-2 emerged from bats and reached humans, likely 
after jumping to pangolin or civet cat intermediate 
hosts [12,13]. Illegal animal trade and wildlife smug-
gling are multibillion-dollar businesses worldwide 
which may enhance the chances of viral assortment 
of coronaviruses from different species; for onward 
transmission to humans, particularly at the wild-
life-human interface [14].
The COVID-19 virus is both infectious and con-













Figure-1: Schematic representation of the roles of bats, civet cats, pangolins and dromedary camels in the epidemiology of 
zoonotic betacoronaviruses, as the major reservoirs and transmitters of the pathogens to humans. Severe acute respiratory 
syndrome coronavirus, Middle East respiratory syndrome coronavirus, and SARS-CoV-2 are transmissible to humans from 
civet cats, dromedary camels, and pangolins, respectively. Human-to-human and human-to-animal transmissions of these 
viruses are very common. 
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people through respiratory droplets and infectious 
fomites. The disease is characterized by a life-threat-
ening and highly contagious pneumonia with the pos-
sibility of failure of one or more organs occurring as 
a complication. The most common symptoms of the 
disease are fever, dry cough, respiratory difficulty, 
shortness of breath, sore throat, chest pain, frequent 
sneezing, and general body malaise. Recent findings 
in 2020 show that the COVID-19 virus can retain 
viability on plastics and stainless steels for approxi-
mately 3 days but does not survive for more than a day 
on cardboard or more than 4 h on copper [15]. Similar 
to other enveloped viruses, soaps and other detergents 
destroy the lipid bilayer of the SARS-CoV-2 envelope 
and inactivate the pathogen.
As an emerging zoonosis, the best treatment 
option for the management of COVID-19 is still 
being determined because there is presently no 
globally approved drug for the treatment. However, 
claims and counterclaims over the efficacy of 
some anti-malaria and antiviral drugs in the man-
agement of the disease have emerged. Although 
chloroquine and hydroxychloroquine were initially 
described as “promising drugs” for the treatment of 
COVID-19 [16], this was later withdrawn due to tox-
icity concerns, particularly at high doses in patients 
with underlying health conditions [17]. In some 
clinical trials, remdesivir – an antiviral drug used 
against Ebola and other viruses – has been described 
as a “promising therapeutic candidate” for the man-
agement of COVID-19 [18]. The drug was said to 
be relatively safe [19] and shortens recovery time 
in hospitalized patients [18,19]. However, unlike 
in Ebola, the efficacy of remdesivir for COVID-
19 treatment is doubtful as it did not meet efficacy 
endpoints in a randomized trial [18]. In addition, 
the drug may not be available or affordable in most 
developing counties. Therefore, the emphasis is on 
the prevention and containment of the disease.
In a bid to limit the morbidity and mortality of 
COVID-19, governments at various levels have imple-
mented several restrictions on human movement and 
interactions, which have taken their toll on the global 
economy and quality of life. Despite these measures, 
the disease is far from being controlled in most parts of 
the world. At present, some countries are even experi-
encing spikes and waves of the infection. During the 
winter/harmattan season, the disease and its untoward 
consequences may even worsen, as obtains in most 
respiratory diseases. The continued spikes and waves 
of COVID-19 in most countries necessitated the need 
to study and analyze the distribution, patterns, and 
determinants of SARS-COV-2 infection worldwide 
in order to restrategize for effective control of the 
pandemic. Therefore, this paper reviewed the global 
epidemiology of SARS-CoV-2 cases and fatalities and 
made suggestions on new measures to tame the tide of 
the rising infection at the global stage and to prevent 
future pandemics or epidemics.
Epidemiology of SARS-CoV-2 Infections
Morbidity of SARS-CoV-2
As of March 1, 2021, SARS-CoV-2 infections 
have been reported in 218 countries/territories across 
all continents [20]. The virus has infected approxi-
mately 120 million people, of whom more than 2.6 
million have died of the disease [20]. Most of the 
active cases have been mild, while less than 2% were 
severe or in critical condition [20]. The top five most 
infected countries (which accounted for 51% of the 
global COVID-19 cases) in decreasing order were the 
US, India, Brazil, Russia, and UK.
The WHO data on the regional distribution of 
SARS-CoV-2 cases as of March 1, 2021, show that the 
Americas, Europe, and Southeast Asia were responsi-
ble for approximately 51 million, 39 million, and 14 
million cases, respectively [20]; which amounted to 
approximately 87% of the global COVID-19 cases 
(Figure-2). The West Pacific and Africa regions 
reported fewer SARS-CoV-2 cases (only 4.3% of the 
global cases). Consequently, the regional distributions 
of SARS-CoV-2 cases in decreasing order were as fol-
lows: The Americas, Europe, Southeast Asia, Eastern 
Mediterranean, Africa, and the West Pacific. The top 
five countries that reported the highest number of 
cases in each of the regions are shown in Table-1. In 
the African region, the South and North sub-regions 
were the epicenters of SARS-CoV-2 infection as these 
areas accounted for most of the reported COVID-19 
cases in Africa [20]. Older adults and the elderly were 
the most affected, as evidenced in the WHO report 
[20] on the age distribution of the infection presented 
in Figure-3.
Infectivity of SARS-CoV-2
The spread of SARS-CoV-2 to over 120 million 
people in approximately 218 countries/territories in 
just about 12 months of its emergence [20] attests to 
the high infectivity of the virus and ease of transmis-
sion. Scientists believe that the new mutant SARS-
CoV-2 variants, particularly the UK (B.1.1.7) and the 





Americas Europe Southeast Asia Eastern Mediterranean
Figure-2: Percentage distribution of the globally confirmed 
cases of severe acute respiratory syndrome coronavirus-2 
across the four most affected WHO regions as at March 1, 
2021 (Source: https://covid19.who.int/).
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and contagious and are therefore driving the current 
surge in COVID-19 cases worldwide. Rapid human 
cross-border movement and viability of the virus under 
certain conditions that are lethal to some other viruses 
may also be enhancing the disease spread. In the dry 
and wet forms, SARS-CoV-2 was reported to have 
retained viability for up to 3 and 7 days respectively, 
at ambient temperature (20-25°C) [21]. The virus also 
retained viability within a pH range of 4-11 for sev-
eral days and for 1-2 days in stool samples preserved 
at room temperature (20-25°C) [21]. However, some 
commonly used disinfectants and laboratory inacti-
vation procedures effectively inactivated or reduced 
viability of the virus [21]. In addition, SARS-CoV-2 
does not survive for more than a day on cardboard 
or more than 4 h on copper [15,21]. These findings 
could be exploited for effective control of the spread 
of COVID-19 in the affected countries/territories.
Mortality of SARS-CoV-2
As of March 1, 2021, there were approximately 
3 million deaths associated with SARS-CoV-2 infec-
tion in 218 countries/territories [20]. More than 75% 
of the global SARS-CoV-2 deaths occurred in 12 coun-
tries, most of which are developed or industrialized 
countries [20]. The top five countries that reported 
the highest number of COVID-19 deaths in descend-
ing order were the US, Brazil, Mexico, India and the 
UK [20]. The distributions of confirmed COVID-19 
fatalities among countries that have reported at least 
1000 cases are shown in Figure-4. The global case-fa-
tality rate of SARS-CoV-2 ranges between 2% and 
3%, but those of Mexico, Italy, Iran, and the UK 
were much higher at 10%, 7.38%, 5.73%, and 5.24%, 
respectively [20]. 
On the continental level, data on COVID-19 
deaths at the European Center for Disease Prevention 
Table-1: Cases, fatalities, and case-fatality rates of SARS-COV-2 in top five most affected countries across each of the 
six WHO regions.








Africa South Africa March 5, 2020 714,246 18,944 2.65
Ethiopia March 13, 2020 92,856 1419 1.53
Nigeria February 27, 2020 61,930 1129 1.82
Algeria February 25, 2020 55,620 1897 3.41
Kenya March 12, 2020 48,490 896 1.85
Americas USA January 20, 2020 8,485,747 223,328 2.63
Brazil February 26, 2020 5,380,635 156,903 2.92
Argentina March 3, 2020 1,081,336 28,612 2.65
Colombia March 6, 2020 1,007,711 30,000 2.98
Mexico February 28, 2020 886,800 88,743 10.01
Eastern Mediterranean Iran February 19, 2020 568,896 32,616 5.73
Iraq February 22, 2020 451,707 10,633 2.35
Saudi Arabia March 2, 2020 344,879 5296 1.54
Pakistan February 26, 2020 327,895 6736 2.05
Morocco March 2, 2020 197,489 3301 1.67
Europe Russia January 31, 2020 1,513,877 26,050 1.72
France January 24, 2020 1,055,942 34,362 3.25
Spain January 31, 2020 1,046,132 34,752 3.32
UK January 31, 2020 854,014 44,745 5.24
Italy January 31, 2020 504,509 37,210 7.38
Southeast Asia India January 30, 2020 7,090,959 119,014 1.68
Bangladesh March 8, 2020 398,515 5803 1.46
Indonesia March 2, 2020 389,712 13,299 3.41
Nepal January 9, 2020 158,089 847 0.54
Myanmar March 23, 2020 44,774 1095 2.25
West Pacific Philippines January 30, 2020 370, 028 6977 1.89
Japan January 16, 2020 97,074 1718 1.77
China December 1, 2019 91, 701 4746 5.18
Singapore January 23, 2020 57,970 28 0.05
Australia January 25, 2020 27,520 905 3.29
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Figure-3: Percentage distribution of globally confirmed 
severe acute respiratory syndrome coronavirus-2 cases 
across different age groups. Adults and the elderly 
accounted for 87% of the cases. (Source: https://covid19.
who.int/).
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and Control as of March 1, 2021 [22], showed that the 
American, European, and Asian continents (in decreas-
ing order) reported the highest number of COVID-19 
fatalities (Figure-5) and accounted for approximately 
94% of the globally reported deaths. The American 
and African continents reported approximately 46% 
and 4% of the globally reported COVID-19 fatalities, 
respectively. The top five countries that reported the 
highest numbers of COVID-19 deaths across each of 
the six WHO regions are shown in Table-1.
Gender and age differences in global COVID-19 cases 
and fatalities
Comprehensive reports on the demographics of 
COVID-19 fatalities at the global or continental lev-
els are difficult to obtain because most countries do 
not indicate gender or age in the reported cases or 
deaths [20]. For example, data from the Centers for 
Disease Control (CDC) showed that as of November 
9, 2020, only 70% and 76% of the reported COVID-
19 fatalities in the America contained information on 
the gender and age of the deceased persons, respec-
tively [23]. Demographic data from the CDC indicated 
that 53% and 47% of COVID-19 deaths in the US 
were males and females, respectively [23]. Similarly, 
a recent study (October 2020) in Mexican hospitals 
showed that 75% of COVID-19 fatalities were men 
with an average age of 62.9 years [24].
The fact that men tend to smoke more and are 
more likely to disregard public health advice on SARS-
CoV-2 prevention protocols may be partly responsible 
for the apparent gender-based bias in global SARS-
CoV-2 susceptibility and mortality [25]. In addition, 
women have more robust immune systems than men 
because they possess a pair of X-chromosomes, which 
unlike the Y-chromosome in men contains most of the 
immune-associated genes [26,27]. The expression of 
angiotensin-converting enzyme-2, which is the main 
receptor for SARS-CoV-2, is higher in males than in 
females [26,27]. Furthermore, female hormones may 
play a role in susceptibility to Coronavirus infections. 
In 2017, scientific evidence showed that female mice 
were less susceptible to SARS-CoV infection than 
males [28]. However, the gender-based differences in 
susceptibility to the virus disappeared following ova-
riectomy, suggesting that the production of estrogen 
may have been responsible for the sex-based vulnera-
bility differences [28].
Furthermore, it appears that SARS-CoV-2 not 
only discriminates by sex but also by age and the 
presence of underlying health conditions. Published 
reports indicate that older adults and the elderly are 
at an increased risk of death following SARS-CoV-2 
infection [29,30]. The age distributions of COVID-19 
mortalities in some countries showed only small vari-
ations, although the number of deaths per country 
showed considerable variation [29]. These findings 
imply that age alone may not be a significant deter-
minant of death following SARS-CoV-2 infection; 
rather, the immune status of the patient and/or pres-
ence of underlying medical condition(s) may play 
prominent roles.
To effectively suppress and/or eliminate SARS-
CoV-2, the host’s immune system must recognize 
Figure-4: Top countries of the world with confirmed coronavirus disease 2019 fatality of at least 1000 cases as at 
November 30, 2020 (Source: https://covid19.who.int/).
Figure-5: Pictorial representation of COVID-19 case-
fatality ratio, as at March 1, 2021, among top four most 
affected continents (Source: https://www.ecdc.europa.eu/
en/geographical-distribution-2019-ncov-cases).
Africa Asia America Europe
Fatalities 103718 360513 1217574 853856
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the virus as an antigen and initiate sufficient humoral 
and/or cellular-mediated immune response to destroy 
and clear off the virus from the body. However, these 
immune mechanisms are usually inadequate in some 
older adults or the elderly [29]. The major preexisting 
comorbidities that negatively influence survival out-
comes in COVID-19 geriatric patients are leukocy-
topenia (particularly lymphopenia and neutropenia), 
hypertension, cardiovascular diseases, type 2 diabetes 
mellitus, kidney diseases, and chronic obstructive pul-
monary diseases [30]. The age susceptibility to COVID-
19 may be due to a significant reduction in innate and 
adaptive immune responses in the elderly [31]. At the 
later stage of life, there is a marked decrease in the 
expression and function of innate immune receptors 
and signal systems, leading to defective activation and 
decreased functionality of the immune cells [24,28-31].
Similarly, as one age, there is a depopulation of 
naive T-lymphocytes in the body as the immature cells 
differentiate into memory T-cells [31]. Unfortunately, 
the replenishment of naive T-lymphocytes decreases 
with age, giving rise to an imbalance in the num-
ber of immune cells and hence the reduced immune 
response to SARS-CoV-2 infection [24,31]. To give 
credence to the above, the lymphocyte-to-neutrophil 
ratio (LNR) and the neutrophil-to-monocyte ratio 
(NMR) in severely ill COVID-19 patients were found 
to be predictors of in-hospital deaths in Mexico [24]. 
Specifically, there were 4-fold decreases in the LNR 
and 2-fold increases in the NMR in patients who died 
of COVID-19 in Mexico [24].
Transmission of SARS-CoV-2
SARS-CoV-2 essentially spreads through inha-
lation [32] and possibly through the fecal-oral route. 
The presence of SARS-CoV-2 RNA has been demon-
strated in stool [33], which might suggest the possi-
bility of transmission through the fecal-oral route, but 
such transmission has not been reported. The inha-
lation of infectious droplets and aerosols produced 
during coughing or sneezing by infected individuals 
is the major means of interpersonal transmission of 
the virus [34]. Respiratory droplets refer to relatively 
heavy infectious agents that are greater or equal to 
5–10 μm in diameter [20]. Proximity of >2 m from the 
infected person seems to be an essential prerequisite 
for transmission through the inhalation of infectious 
droplets because the droplets; are relatively heavy and 
do not usually travel more than 2 m before settling on 
surfaces [32]. The virus also spreads through contact 
with contaminated surfaces (fomites) in the immediate 
surroundings of infected persons [34]. SARS-CoV-2 
RNA has been detected in semen [35] and breast milk 
[36] of infected persons, but there has not been any 
evidence of the transmission through coitus or breast-
feeding. Evidences of SARS-CoV-2 infections in pets, 
various farm animals, and wildlife have also been 
reported  [37,38], and proofs of zoonotic transmission 
of the virus have been documented [39,40].
COVID-19 in developing and malaria-endemic 
countries
Contrary to the pessimistic predictions on the 
possible devastating morbidity and mortality of 
SARS-CoV-2 in developing countries, which are back-
ward in terms of health-care facilities and services, 
it is somewhat surprising that these countries have 
recorded minimal numbers of COVID-19 cases and 
deaths. For example, as of March 1, 2021, data posted 
on the COVID-19 dashboard of the European Center 
for Disease Prevention and Control [22] indicated that 
Africa contributed only approximately 3.3% and 4% 
of the 120 million cases and 2.6 million COVID-19 
deaths, respectively [22]. The reasons behind the low 
COVID-19 cases and mortalities in developing coun-
tries have been mostly speculative or elusive, but a 
few factors may be responsible.
Prominent among these factors may be low test-
ing for COVID-19 and the lack of medical reports 
on the causes of deaths due to home management 
of suspected COVID-19 cases. For example, in 
Nigeria, which is the seventh most populated coun-
try worldwide with an estimated population of 207 
million [41], data provided by the Nigeria Centre 
for Disease Control showered that only 1,489,103 
COVID-19 tests had been conducted as of February 
27, 2021 [42]. Of those tested, 155,076 were positive, 
corresponding to a test-positivity ratio of 9.6 (10.4% 
of those tested were positive). The total number tested 
represented only 0.72% of the population. It is most 
likely that if more tests were conducted, the number 
of reported cases would have been much higher. The 
same scenario may be playing out in other develop-
ing countries and thus may be responsible for the 
low number of COVID-19 cases and deaths being 
reported. Furthermore, scientific evidences suggest 
that the elderly and those with underlying health con-
ditions are most disproportionately affected [29,30]. 
In Africa, these groups of people often reside in dis-
persed rural settings [43] where COVID-19 testing 
may be unlikely.
There seems to be a negative correlation between 
SARS-CoV-2 infections/deaths and malaria endemic-
ity/exposure. The number of COVID-19 cases per 
million was negatively correlated with malaria ende-
micity in 108 countries across the globe [44]. Malaria-
free countries not only recorded higher numbers of 
COVID-19 infections but also reported more fatalities 
compared with high malaria-endemic countries [44]. 
These findings suggest that natural immune responses 
against malaria may provide heterologous protection 
against SARS-CoV-2, and this may explain the low 
morbidity and mortality rates of COVID-19 in devel-
oping and malaria-endemic countries. The correlation 
may also explain the prima facie justification for the use 
of antimalarial drugs (chloroquine and hydroxychloro-
quine) in the management of COVID-19 [16,17].
Certain antimalarial drugs have been shown 
to possess some antiviral activities that inhibit the 
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receptors responsible for the adhesion and binding 
of SARS-CoV-2 to human cell [45]. The drugs also 
limit the replication of the virus by blocking the lyso-
somal and enzymatic activities required for the pro-
cess. These antiviral activities may help to curtail the 
overactivation of the immune system in COVID-19 
patients, thereby slowing the progression and severity 
of the disease [45]. 
Finally, the youthful population of most devel-
oping countries, particularly in Africa, may explain 
the low COVID-19 morbidity and mortality rates 
reported. Nineteen of the world’s 20 youngest coun-
tries are in Africa [43]. Since youthful populations 
appear to be less susceptible to SARS-CoV-2 infec-
tion and may also fight off the condition better than 
the elderly population [29], the low morbidity and 
mortality rates of COVID-19 in Africa are, therefore, 
not entirely surprising.
Lessons for effective control of COVID-19 and other 
possible future pandemics
Epidemiologically speaking, “control” is the 
first and most crucial step toward the elimination/
eradication of diseases that have attained an epidemic 
or pandemic status. This necessitated the lockdowns, 
border closures, travel bans, and other forms of social 
restrictions imposed by various governments across 
the globe. However, these measures have not fully 
achieved the desired result because COVID-19 is 
neither controlled nor eradicated at the global stage. 
Instead, there have been spikes and waves of the 
infection in most countries to the extent that some of 
these nations are currently enforcing third lockdowns 
despite the associated severe economic and social 
consequences.
Cognizant of the foregoing situation, there are 
several pertinent questions to ask. What is wrong with 
the current containment measures being deployed? 
Why has the epidemiologic curve of COVID-19 
refused to flatten in most countries? Why are we 
experiencing spikes and waves of COVID-19 when 
the incidence should be decreasing? Are lockdown 
and other forms of social restrictions the only way 
out of this pandemic? Should we consider a different 
approach for the disease control as COVID-19 vac-
cines are being rolled out? There are no easy answers 
to these questions, but drawing inferences from past 
and present epidemics/pandemics may provide some 
lessons for the effective control of this and future pan-
demics, as suggested below.
1. Rather than total lockdown and border closure, 
aggressive testing, contact tracing, case isolation, 
and quarantine of exposed individuals may suf-
fice. For example, in China, where the pandemic 
first emerged, lockdowns and travel restrictions 
only delayed the overall epidemic progression 
by just 3-5 days [46]. However, these restric-
tions decreased international case importation 
of COVID-19 by approximately 80% [46]. This 
implies that while border closure effectively 
prevented case importation or exportation of the 
virus, lockdowns within the country only delayed 
but did not prevent the disease spread. It also 
implies that lockdowns, despite the economic and 
social implications, cannot completely prevent 
interpersonal interactions and hence the disease 
spread. It is possible that preventing case impor-
tation through timely border closure and intracity 
spread of the disease through aggressive testing, 
contact  tracing, isolation of confirmed cases, and 
quarantine of suspected or exposed individuals 
could have sufficed. However, border closure as 
a means of containment of a pandemic must be 
implemented before the disease is imported or the 
purpose of the closure will be ultimately defeated.
2. Enacting impromptu social restriction rules alone 
may not be enough to contain an infectious or 
contagious disease that has attained a pandemic 
status. This likely explains why social restriction 
measures deployed against COVID-19 have not 
eliminated the disease spread in most affected 
countries. Instead, there have been waves of 
the disease despite restrictions. There is a need 
to continuously and systematically educate or 
engage the masses on the need to obey these rules 
for public health safety. For example, most per-
sons in Nigeria still believe that COVID-19 is 
a hoax, and they only use face masks in public 
to evade police harassments [47]. In addition, in 
South Africa, people jettison social distancing 
rules during funerals and religious gatherings, 
and this is thought to have been the primary cause 
of COVID-19 spikes, ravaging the country more 
than any other in Africa [48]. These findings 
underscore the need for increased public enlight-
enment of the importance of obeying the recom-
mended public health protocols for COVID-19 
prevention.
 Various governments have already done a lot in 
this regard. However, in some countries, people 
do not always trust their government and hence 
may dismiss any information from the political 
leaders as mere politicians’ statements. Where the 
above is the case, the government should engage 
respected religious, traditional, or community 
leaders for adequate public enlightenment since 
these individuals may command much public 
trust. Since the government alone cannot cater for 
all the needs in society, cooperative bodies, chari-
ties, and non-governmental organizations can lead 
a sustained grass-roots public enlightenment cam-
paign against COVID-19.
3. There is a need for political leaders to obey the 
recommended public health directives to control 
COVID-19 and put systems in place to make it 
easier for citizens to comply with the rules. For 
example, the rule on compulsory use of face 
masks in public places could be accompanied by 
the free distribution of the same to people who 
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cannot afford them. Facilities for hand sanitizing 
and/or disinfection could be mounted at strategic 
public places such as markets, schools, and places 
of worship. Palliatives and all forms of social 
benefits should be provided, particularly to the 
unemployed, to enable them to cope with stay-at-
home orders. As this is on-going, contact tracing 
systems, isolation of all cases, and quarantining of 
contacts should be intensified. These actions can 
flatten the epidemiologic curve faster and hence 
prevent subsequent mandatory stay-at-home order 
for everyone.
4. The disparities in gender and age vulnerability to 
COVID-19 infections and fatalities emphasize the 
need to tailor the disease treatment, when found, 
according to sex and age. Since the Rhesus-
positive (O+) blood group was the least affected 
by SARS-CoV-2 in Sudan [49], the search for 
COVID-19 treatment could also evaluate the 
ABO blood grouping system to unravel the mys-
tery behind the disease survivability based on 
blood groups.
5. It is pertinent to limit unnecessary human incur-
sions into wildlife habitats and other forms of 
exposure to animal reservoirs of zoonotic patho-
gens. In the last few years, the world has expe-
rienced various epidemics, including avian flu, 
SARS-CoV, swine flu, MERS-CoV, Ebola, and 
now SARS-CoV-2. All these epidemics/pan-
demic/public health emergencies have been linked 
to animals, particularly wildlife [50]. It may be 
time to rethink all forms of needless human-an-
imal interactions, including having wild animals 
as pets, hunting bats for meat during bat festivals, 
and illegal wild animal trade, particularly at the 
international level [14,51]. These practices facil-
itate inter- and intra-species spread of zoonotic 
viruses and make it easy for these pathogenic 
viruses to jump species levels. Therefore, cur-
tailing unwarranted exposure to wildlife through 
advocacy and international legislation that could 
be implemented using a coordinated One Health 
approach may be worthwhile.
6. There is a need for epidemic preparedness and 
strengthening of the health system, particularly 
in developing countries. This could be achieved 
through increased budgetary allocations to the 
health sector and enhanced surveillance for emerg-
ing and reemerging infections. Since health work-
ers are critical for a rapid response to any epidemic 
or pandemic, they should be well remunerated, and 
adequate personal protective equipment provided 
at all times. Additionally, international partnerships 
for active surveillance against emerging zoonoses 
and prompt reporting of strange diseases are par-
amount for timely detection of early disease warn-
ings and to avert future epidemics or pandemics.
7. The six major identified strains (L, S, V, G, GR, 
and GH strains) of SARS-CoV-2 [52], as well 
as the highly infectious new variant strains first 
detected in the UK, South Africa and recently in 
Brazil [53], should be incorporated in the various 
COVID-19 vaccines being produced. The UK 
and South African mutants strains are about 70% 
more infectious, have been detected in over 100 
countries and territories [20] and are also the pre-
dominant strains spreading in European and the 
American continents [54]. Therefore, incorpora-
tion of these and indeed all identified strains of 
SARS-CoV-2 in the various COVID-19 vaccines 
being produced will greatly enhance their protec-
tion spectrum. This is paramount because the vul-
nerability of COVID-19 survivors to subsequent 
SARS-CoV-2 infections suggests that the anti-
bodies to various strains of the virus may not be 
cross-protective or that the natural immunity may 
be transient.
8. Since ambient temperature and humidity seem to 
adversely affect the viability and spread of SARS-
CoV-2 [55], this useful epidemiological finding 
could help countries and health institutions make 
better plans for the provision of effective health 
services during the winter, when the disease is 
expected to surge due to cold weather conditions.
Conclusion
As the effort to effectively control the pandemic 
intensifies, there is a need to maintain a healthy bal-
ance between saving lives and livelihoods in imple-
menting disease containment measures. Rather than a 
total lockdown, early border closure on notification of 
an exotic disease or epidemic outbreak may suffice for 
the prevention of international case importation. There 
is a need for epidemic preparedness and strengthen-
ing of the health system, particularly in developing 
countries. Illegal trade in wild animals and all unwar-
ranted human-animal interactions, particularly at the 
human-wildlife interface, should be curtailed. All the 
identified SARS-CoV-2 strains, including the highly 
infectious new variant strains found in the UK, South 
Africa, Europe, Brazil, and the US, should be incorpo-
rated in COVID-19 vaccines to widen the protection 
spectrum. More public enlightenment and advocacy are 
required for the acceptance of COVID-19 vaccines and 
strict compliance with the disease prevention protocols. 
Primary inoculation with COVID-19 vaccine, booster 
vaccination after 2-4 weeks and annual revaccination 
is required for adequate immunization against SARS-
CoV-2. Survivors of COVID-19 may only require single 
dozing and annual revaccination thereafter. Adoption 
of One Health approach and development of globally 
coordinated active surveillance systems against emerg-
ing and reemerging zoonotic viruses is imperative to 
nip future epidemics/pandemics at the bud.
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